Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, BMS-986094, Ribavirin, Placebo for BMS-986094
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Healthy, Hepatitis C
Interventions
BMS-986094/INX-08189, Placebo matching BMS-986094/INX-08189
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Saint Paul, Minnesota • Knoxville, Tennessee + 1 more
Conditions
Healthy
Interventions
INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Hepatitis C
Interventions
200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas